rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Hyperion DeFi, Inc.

HYPD · Nasdaq

Health CareBiotechnologyNot moving yet

HYPD stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 7.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 2
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$771K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
32 (+9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$686KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8
Sale orders, 12 months0
Buyers · sellers5 · 0
WhoDidSharesTraded
Hyunsu JungDirector, Officerbought500at $3.642 Jun 2026filed 2 Jun 2026
Hyunsu JungDirector, Officerbought500at $3.682 Jun 2026filed 2 Jun 2026
Hyunsu JungDirector, Officerbought5,000at $3.661 Jun 2026filed 2 Jun 2026
Hyunsu JungDirector, Officerbought2,000at $3.811 Jun 2026filed 2 Jun 2026
David R. KnoxChief Financial Officerbought27,950at $3.5931 Dec 2025filed 5 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders32+9 on the quarter
New · exited14 · 5
Reported value$8.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 2026466,798$1.5M+466,798
FRANKLIN RESOURCES INCnew · filed 13 Aug 2026395,939$1.2M+395,939
Arrington Capital Management, LLCnew · filed 11 Aug 2026297,777$935K+297,777
MORGAN STANLEYunchanged · filed 13 Aug 2026237,986$747K00.0%
Almanack Investment Partners, LLC.new · filed 30 Jul 2026169,013$531K+169,013
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026130,707$410K+53,627+69.6%
JANE STREET GROUP, LLCreduced · filed 14 Aug 2026127,491$400K-789−0.6%
OPPENHEIMER & CO INCadded · filed 3 Aug 2026126,365$397K+62,097+96.6%
BlackRock, Inc.added · filed 7 Aug 2026114,400$359K+33,292+41.0%
GOLDMAN SACHS GROUP INCnew · filed 14 Aug 202691,390$287K+91,390
31 Mar 2025 – 30 Jun 2026
162431Mar 25Jun 25Dec 25Mar 26Jun 26

Everyone who traded it

David R. Knox Company insiderChief Financial Officer · last 29 Sep 20261 · 0
Hyunsu Jung Company insiderDirector, Officer · last 16 Aug 20262 · 0
Ellen R. Strahlman Company insiderDirector · last 30 Jun 20269 · 0
Happy David Walters Company insiderDirector · last 30 Jun 20261 · 0
Michael S. Geltzeiler Company insiderDirector · last 30 Jun 20261 · 0
Rachel Jacobson Company insiderDirector · last 30 Jun 20260 · 0
Robert Rubenstein Company insiderGeneral Counsel · last 12 Jan 20260 · 0
Michael M. Rowe Company insiderChief Executive Officer · last 13 Jun 202512 · 0
Bren Kern Company insiderChief Operating Officer · last 21 Apr 20251 · 0
Charles E. Mather IV Company insiderDirector · last 21 Apr 20259 · 0
Ram Palanki Company insiderDirector · last 21 Apr 20250 · 0
Tsontcho Ianchulev Company insiderDirector · last 21 Apr 20255 · 5

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202562.7%
Return on capital employedFY 2025 · to 31 Dec 2025-95.2%
Research spendFY 2025 · to 31 Dec 2025235%
Share count trendFY 2025 · to 23 Mar 202631.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.4M

Analyst forecasts

No analyst forecasts yet.